Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

Park, Chansub; Park, Kyeongmee; Kim, Jiyoung; Sin, Youngjoo; Park, Inseok; Cho, Hyunjin; Yang, Keunho; Bae, Byung Noe; Kim, Ki Whan; Ahn, Seung-Ho; Gwak, Geumhee

doi:10.1186/s12957-016-0999-x

Cited by 21 publications

(13 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings were similar to the findings of Bae et al, which indicated that a significant difference in prognosis between single HoR-positive tumors and double HoR-positive tumors, was only observed in HER2-negative tumors, and not in HER2-positive tumors 20 . Several studies also confirmed that single HoR-positive tumors showed worse prognosis than double HoR-positive tumors in the HER2negative group [21][22][23][24] . No significant effect of single HoR-positive tumors in the prognostic assessment of HER2-positive tumors may be related to the results of trastuzumab treatment.…”

Section: Discussionmentioning

confidence: 87%

Incorporation of biologic factors for the staging of de novo stage IV breast cancer

Lian

Wang

et al. 2020

npj Breast Cancer

View full text Add to dashboard Cite

This study aimed to investigate the prognostic value of biological factors, including histological grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status in de novo stage IV breast cancer. Based on eligibility, patient data deposited between 2010 and 2014 were collected from the surveillance, epidemiology, and end results database. The receiver operating characteristics curve, Kaplan–Meier analysis, and Cox proportional hazard analysis were used for analysis. We included 8725 patients with a median 3-year breast cancer-specific survival (BCSS) of 52.6%. Higher histologic grade, HER2-negative, ER-negative, and PR-negative disease were significantly associated with lower BCSS in the multivariate prognostic analysis. A risk score staging system separated patients into four risk groups. The risk score was assigned according to a point system: 1 point for grade 3, 1 point if hormone receptor-negative, and 1 point if HER2-negative. The 3-year BCSS was 76.3%, 64.5%, 48.5%, and 23.7% in patients with 0, 1, 2, and 3 points, respectively, with a median BCSS of 72, 52, 35, and 16 months, respectively (P < 0.001). The multivariate prognostic analysis showed that the risk score staging system was an independent prognostic factor associated with BCSS. Patients with a higher risk score had a lower BCSS. Sensitivity analyses replicated similar findings after stratification according to tumor stage, nodal stage, the sites of distant metastasis, and the number of distant metastasis. In conclusion, our risk score staging system shows promise for the prognostic stratification of de novo stage IV breast cancer.

show abstract

Section: Discussionmentioning

confidence: 87%

Incorporation of biologic factors for the staging of de novo stage IV breast cancer

Lian

Wang

et al. 2020

npj Breast Cancer

View full text Add to dashboard Cite

show abstract

“…This is not consistent with findings from previous studies which did not find significant associations with HER2 positivity and tumour grade or size[ 11 - 14 ]. We hypothesize that this may be due the smaller sample sizes in those studies and the heterogeneity of HER2+ ILC[ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

Kee¹,

Tan²,

Sultana³

et al. 2020

WJCO

View full text Add to dashboard Cite

BACKGROUND Invasive lobular carcinomas (ILC) form 5%-10% of breast cancer and rarely show overexpression of human epidermal growth factor receptor 2 ( HER2 ). AIM To describe the prevalence and prognostic factors of HER2 positive ( HER2+ ) ILC in an Asian population. METHODS A retrospective review of patients with ILC seen between January 1985 and March 2018 at various SingHealth medical institutions was conducted. Demographic and clinical data were collected from medical records. We examined clinicopathological characteristics and survival in relation to HER2 status. RESULTS A total of 864 patients were included. Prevalence of HER2 positivity was 10.1% (87 patients). Compared with HER2 negative ( HER2- ) ILC, HER2+ ILC was associated with a higher proportion of estrogen receptor negative (24.4% vs 5.9%, P < 0.001), progesterone receptor negative ( PR- ) (40.2% vs 24%, P = 0.002) and grade 3 tumours (Grade 3, 29.0% vs 10.2%, P < 0.001). Overall survival rate was poorer in patients with HER2+ compared to HER2- ILC (56.7% vs 72.9% alive at 10 years; hazard ratio 1.87, 95% confidence interval: 1.21-2.90, P = 0.004). Based on multivariate analysis, negative prognostic factors for overall survival included HER2 positivity, PR negativity, older age, Indian ethnicity and higher tumour stage. CONCLUSION Prevalence of HER2+ ILC was 10.1%. HER2+ ILC was more likely to have poorer prognostic features such as estrogen receptor negative, PR- and higher tumour grade, and have a poorer survival.

show abstract

“…Based on the expression of ER, PR, and/or HER2, breast cancer is commonly classified into four main subtypes: luminal A, luminal B, HER2-enriched, and basal-like subtypes [28–31]. Luminal-type breast tumors with ER+ and/or PR+ show a positive response to hormone therapy [32, 33]. A previous study showed that PNPO is induced by estradiol and 4-hydroxytamoxifen in T47D and MCF7 cells (both ER+/PR+), but not in MDA-MB-231 (ER-/PR-) cells [34], implicating that PNPO may correlate with the hormone-related treatment.…”

Section: Discussionmentioning

confidence: 99%

Pyridoxine 5′-phosphate oxidase is correlated with human breast invasive ductal carcinoma development

Ren

Guan

Zhang

et al. 2019

Aging

View full text Add to dashboard Cite

Pyridoxine 5′-phosphate oxidase (PNPO) is a converting enzyme for an active form of vitamin B6. This study aims to evaluate the biological function and the regulatory mechanism of PNPO in human breast invasive ductal carcinoma (IDC). We unveiled for the first time that PNPO was upregulated in patients with IDC and was correlated with the overall survival of patients with metastasis at the later stages. Suppression of PNPO inhibited breast cancer cell proliferation, migration, invasion and colony formation, arrested cell cycle at the G2/M phase and induced cell apoptosis. PNPO was positively correlated with lncRNA MALAT1 which was negatively correlated with miR-216b-5p. PNPO was down-regulated and up-regulated by miR-216b-5p mimics and inhibitors, respectively, in breast cancer cells. A microRNA response element was found in both PNPO and MALAT1 transcripts for miR-216b-5p and the dual-luciferase reporter assay confirmed the binding of these transcripts. Knockdown of MALAT1 resulted in an increase of miR-216b-5p and a decrease of PNPO mRNA, indicating a regulatory mechanism of competing endogenous RNAs. Taken together, these results reveal the biological function and a regulatory mechanism of PNPO, in which the MALAT1/miR-216b-5p/PNPO axis may be important in IDC development. Targeting this axis may have therapeutic potential for breast cancer.

show abstract

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

Cited by 21 publications

References 37 publications

Incorporation of biologic factors for the staging of de novo stage IV breast cancer

Incorporation of biologic factors for the staging of de novo stage IV breast cancer

Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

Pyridoxine 5′-phosphate oxidase is correlated with human breast invasive ductal carcinoma development

Contact Info

Product

Resources

About